This site is intended for healthcare professionals

Bavencio + axitinib combination accepted for use within NHS Scotland for the first-line treatment of adult patients with advanced renal cell carcinoma. Merck KGaA + Pfizer

Read time: 1 mins
Last updated:16th Mar 2021
Published:13th Oct 2020
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest